VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 356 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2016. The put-call ratio across all filers is 1.00 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2016 | $42,947,000 | -73.4% | 1,633,000 | +2.9% | 0.87% | -71.1% |
| Q4 2015 | $161,310,000 | -34.1% | 1,586,925 | +15.6% | 3.02% | -35.0% |
| Q3 2015 | $244,824,000 | -21.0% | 1,372,490 | -1.7% | 4.64% | -14.5% |
| Q2 2015 | $310,099,000 | +15.3% | 1,395,900 | +3.1% | 5.42% | +6.9% |
| Q1 2015 | $269,021,000 | +38.7% | 1,354,455 | -0.0% | 5.07% | +27.7% |
| Q4 2014 | $193,909,000 | +11.3% | 1,354,970 | +2.0% | 3.97% | -3.1% |
| Q3 2014 | $174,262,000 | +4.0% | 1,328,220 | 0.0% | 4.10% | +2.9% |
| Q2 2014 | $167,515,000 | -16.0% | 1,328,220 | -12.2% | 3.98% | -17.3% |
| Q1 2014 | $199,396,000 | +13.5% | 1,512,530 | +1.1% | 4.81% | +12.7% |
| Q4 2013 | $175,669,000 | +14.1% | 1,496,330 | +1.4% | 4.27% | +3.7% |
| Q3 2013 | $154,023,000 | +27.3% | 1,476,310 | +5.1% | 4.12% | +11.4% |
| Q2 2013 | $120,970,000 | – | 1,405,325 | – | 3.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |